Literature DB >> 28282307

Health-Related Quality of Life After the Diagnosis of Locally Advanced or Advanced Prostate Cancer: A Longitudinal Study.

Leah Zajdlewicz1, Melissa K Hyde, Stephen J Lepore, Robert A Gardiner, Suzanne K Chambers.   

Abstract

BACKGROUND: Approximately 20% of men with a diagnosis of prostate cancer present with locally advanced or advanced disease. Few studies consider longer-term impact of disease progression and treatment adverse effects on health-related quality of life (QoL) of these men.
OBJECTIVE: Describe changes in health-related QoL over 5 years for men with newly diagnosed locally advanced or advanced prostate cancer. INTERVENTIONS/
METHODS: Eighty-one men with locally advanced or advanced prostate cancer referred to the study by their treating urologist completed a self-administered questionnaire assessing distress, cancer-specific distress, decision regret, satisfaction with life, and global and disease-specific health-related QoL. Questionnaires were administered close to diagnosis (baseline), 2, 6, 12, 24, 36, 48, and 60 months' follow-up.
RESULTS: Men were of mean age 68.3 (SD, 7.9) years and at mean of 31.9 (SD, 50.5) days postdiagnosis. The most common treatment received was androgen deprivation therapy (95.1%) or radiation therapy (79%). The proportion of men classified as distressed (Distress Thermometer) ranged from 46.3% (baseline) to 32.6% (60 months). Decrements in physical QoL were found at 2, 6, 12, 24, 36, and 48 months compared with baseline. Life satisfaction ratings were lower at 6 months compared with baseline. Sexual concerns were consistently high across the 5 years (Expanded Prostate Cancer Index Composite <30).
CONCLUSIONS: In the context of advanced disease, results indicate that health-related QoL fluctuates from diagnosis to 5 years later. A substantial proportion remained distressed at 5-year follow-up. IMPLICATIONS FOR PRACTICE: Care frameworks supporting ongoing assessment of health-related QoL concerns of men with advanced prostate cancer are needed with a particular focus on sexual adjustment.

Entities:  

Mesh:

Year:  2017        PMID: 28282307     DOI: 10.1097/NCC.0000000000000432

Source DB:  PubMed          Journal:  Cancer Nurs        ISSN: 0162-220X            Impact factor:   2.592


  9 in total

1.  Life style and interaction with microbiota in prostate cancer patients undergoing radiotherapy: study protocol for a randomized controlled trial.

Authors:  Patrizia Gnagnarella; Giulia Marvaso; Barbara Alicja Jereczek-Fossa; Ottavio de Cobelli; Maria Claudia Simoncini; Luiz Felipe Nevola Teixeira; Annarita Sabbatini; Gabriella Pravettoni; Harriet Johansson; Luigi Nezi; Paolo Muto; Valentina Borzillo; Egidio Celentano; Anna Crispo; Monica Pinto; Ernesta Cavalcanti; Sara Gandini
Journal:  BMC Cancer       Date:  2022-07-19       Impact factor: 4.638

2.  Effects of the Heart to Heart Card Game for Patients with Advanced Cancer Receiving Home-Based Palliative Care: A Clinical Randomized Controlled Trial.

Authors:  Jiayi Du; Ling Fu; Jiaxin Cui; Zifen An; Pei Fang; Lanhui Tan; Xianmei Meng; Liping Yu
Journal:  Int J Environ Res Public Health       Date:  2022-05-17       Impact factor: 4.614

3.  Mood, sexuality, and relational intimacy after starting androgen deprivation therapy: implications for couples.

Authors:  Lauren M Walker; Pablo Santos-Iglesias; John Robinson
Journal:  Support Care Cancer       Date:  2018-05-18       Impact factor: 3.603

4.  A systematic review of physical activity-based behaviour change interventions reaching men with prostate cancer.

Authors:  A Finlay; G Wittert; C E Short
Journal:  J Cancer Surviv       Date:  2018-05-16       Impact factor: 4.442

5.  Technology-Based Psychosocial Intervention to Improve Quality of Life and Reduce Symptom Burden in Men with Advanced Prostate Cancer: Results from a Randomized Controlled Trial.

Authors:  Frank J Penedo; Rina S Fox; Laura B Oswald; Patricia I Moreno; Cody L Boland; Ryne Estabrook; Heather L McGinty; David C Mohr; Mark J Begale; Jason R Dahn; Sarah C Flury; Kent T Perry; Shilajit D Kundu; Betina Yanez
Journal:  Int J Behav Med       Date:  2020-10

6.  Symptom burden profiles in men with advanced prostate cancer undergoing androgen deprivation therapy.

Authors:  Blanca Noriega Esquives; Tae K Lee; Patricia I Moreno; Rina S Fox; Betina Yanez; Gregory E Miller; Ryne Estabrook; Mark J Begale; Sarah C Flury; Kent Perry; Shilajit D Kundu; Frank J Penedo
Journal:  J Behav Med       Date:  2022-02-02

7.  Community pharmacy lifestyle intervention to increase physical activity and improve cardiovascular health of men with prostate cancer: a phase II feasibility study.

Authors:  Agnieszka Lemanska; Karen Poole; Bruce A Griffin; Ralph Manders; John M Saxton; Lauren Turner; Joe Wainwright; Sara Faithfull
Journal:  BMJ Open       Date:  2019-06-11       Impact factor: 2.692

8.  Factors contributing to the ceiling effect of the EQ-5D-5L: an analysis of patients with prostate cancer judged "no-problems".

Authors:  Hideki Murasawa; Takayuki Sugiyama; Yuki Matsuoka; Takashi Okabe; Yoshiaki Wakumoto; Nobumichi Tanaka; Mikio Sugimoto; Masafumi Oyama; Kiyohide Fujimoto; Shigeo Horie; Masaru Funagoshi; Ichiro Arakawa; Shinichi Noto; Kojiro Shimozuma
Journal:  Qual Life Res       Date:  2019-10-03       Impact factor: 4.147

9.  Prostate cancer survivorship essentials framework: guidelines for practitioners.

Authors:  Jeff Dunn; Anna Green; Nicholas Ralph; Robert U Newton; Andrew Kneebone; Mark Frydenberg; Suzanne K Chambers
Journal:  BJU Int       Date:  2020-08-18       Impact factor: 5.969

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.